These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31287200)

  • 1. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
    Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
    Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
    Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
    Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S
    J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib in the management of Waldenstrom macroglobulinemia.
    Yosef A; Touloukian EZ; Nambudiri VE
    J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib-induced acute liver failure.
    Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
    Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
    [No Abstract]   [Full Text] [Related]  

  • 11. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
    Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
    Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
    Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
    N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
    PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
    Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
    Tomcsányi J; Nényei Z; Mátrai Z; Bózsik B
    JACC Clin Electrophysiol; 2016 Dec; 2(7):847-849. PubMed ID: 29759770
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
    Hartsell L; Janes A; Larck C; Park S; Arnall JR
    J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
    Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
    Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.